Semiconductor AI Medical Tech Stock Butterfly Network (NYSE: BFLY) Soars on Update on Full Body Ultrasound Scanner
Butterfly Network (NYSE: BFLY) shares rose about 33% to $7.61 (+33.19%) on volume above 16 million after the company commented on Midjourney Medical’s announcement of a full-body tomographic ultrasound scanner. Butterfly said the prototype uses 40 of its Ultrasound-on-Chip imaging modules under a co-development deal, with more modules planned. Butterfly also noted up to $74 million in expected payments over five years disclosed in a Nov. 17, 2025 8-K.
Near-term sentiment is likely positive as the company links its chip platform to a high-visibility whole-body scanner concept and reiterates deal economics.
Butterfly Network says it will support Midjourney Medical’s full-body ultrasound scanner using 40 Ultrasound-on-Chip modules under a co-development deal.
Shares may remain bid on continued media/retail attention and webinar follow-through, but follow-through depends on commercialization details beyond the prototype.
Background
Butterfly Embedded (formerly Octiv) licenses its Ultrasound-on-Chip and co-develops imaging applications; the company previously disclosed the Midjourney agreement terms in an 8-K dated Nov. 17, 2025.
Why it matters
The key incremental trading driver is management’s same-day commentary tying Butterfly’s chip modules to Midjourney Medical’s announced full-body tomographic scanner, plus a scheduled webinar to discuss commercial opportunity.
Market relevance
A same-day partnership commentary around a whole-body ultrasound scanner can sustain momentum trading in BFLY, but the article lacks new financial guidance or confirmed deployment milestones.
Market effects
Reinforces the ultrasound/AI-on-device narrative and could lift sentiment for semiconductor-enabled medical imaging platforms.
Primarily US-listed medical tech sentiment; limited direct regional spillover described.
Whole-body imaging concept and “no radiation” positioning may attract international attention, but no global regulatory/market data is provided.
Alternative perspectives
The collaboration is framed around a prototype and a co-development/licensing arrangement; without confirmed adoption, revenue timing may be distant and the move could fade.
The article references an earlier 8-K for payment terms (up to $74M over five years), so incremental valuation impact may be smaller than the headline price action suggests.
Key entities
- companyButterfly Network, Inc.
NYSE-listed ultrasound semiconductor and software company; subject of the alert and the Midjourney collaboration commentary.
- companyMidjourney Medical
Announced a full-body tomographic imaging scanner; collaboration is enabled via Butterfly’s Ultrasound-on-Chip licensing/co-development.
- venueTD Cowen
Broker/dealer hosting the Emerging Growth Webinar where Butterfly management will discuss the collaboration.
